Do GLP-1s Change the Meaning of "Obesity"?

With the advent of GLP-1 drugs, it was only a matter of time before Brad and Gabriel dove into a discussion about this controversial drug class and the equally contentious disease, obesity. In this episode, they explore a range of topics—from the history of obesity and its recognition as a disease to how GLP-1s like Ozempic are influencing the conversation around the legitimacy and stigma of obesity beyond just Body Mass Index (BMI).

One of the most compelling ideas from this thought-provoking episode centers on control—how we perceive our own health and judge others, assuming people have more control over their health outcomes than they really do. This theme cuts to the heart of the obesity debate: are we excusing unhealthy habits, or are we acknowledging that the issue is far more complex than we originally thought?

The inspiration for this episode: https://www.nytimes.com/2024/09/19/opinion/obesity-disease-ozempic-weight-loss.html

If you have any questions, feedback, or just want to say hi, email us at medicalanthropology@havas.com

Check out Breaking the Code on LinkedIn: https://www.linkedin.com/company/breaking-the-code-havas-health-and-you-podcast